What is TelyRx?
TelyRx operates as a high-growth digital health platform that bridges the gap between licensed medical providers and patients requiring convenient access to medication. By facilitating online prescriptions and rapid home delivery, the company addresses critical inefficiencies in the healthcare delivery model. Currently serving a patient base exceeding 200,000 individuals, TelyRx has established a robust infrastructure that supports chronic illness management, mental health support, and lifestyle-related pharmaceutical needs. The platform effectively removes the friction of in-person clinical visits, positioning itself as a leader in the burgeoning telehealth and e-pharmacy market segment.
How much funding has TelyRx raised?
TelyRx has raised a total of $12.6M across 1 funding round:
Stock/Share Issuance
$12.6M
Stock/Share Issuance (2026): $12.6M, investors not publicly disclosed
Key Investors in TelyRx
Undisclosed Investors
What's next for TelyRx?
With this major enterprise-level funding, TelyRx is expected to prioritize the expansion of its provider network and the optimization of its logistics capabilities. The strategic focus will likely shift toward enhancing the digital patient experience and integrating more sophisticated data analytics to improve health outcomes. As the company scales, it will likely explore deeper partnerships with insurance providers and health systems to solidify its market position. The capital will serve as a catalyst for further technological innovation, ensuring that TelyRx remains at the forefront of the shift toward decentralized, patient-centric healthcare delivery.
See full TelyRx company page
